New treatment approach shows promise for relapsed Hodgkin’s lymphoma

Adults with hard to treat Hodgkin’s lymphoma who were given brentuximab vedotin immediately after stem cell transplantation survived without the disease progressing for twice as long as those given placebo, a phase III randomised controlled trial published in the Lancet shows.1

Brentuximab vedotin, the first new drug for Hodgkin’s lymphoma in over 30 years, is an antibody attached to a powerful chemotherapy drug that targets the CD30 protein on Hodgkin’s lymphoma cells. It has recently been approved for relapsed or refractory Hodgkin’s lymphoma …